Highlights

  • De.mem’s September 2026 quarterly activities report disclosed approximately AUD 10.1 million in cash receipts, a 29% increase on the prior corresponding period.
  • The company supplies water and wastewater treatment services, chemicals, consumables and membrane technologies to industrial customers.
  • De.mem’s September-quarter report covered ongoing membrane technology development alongside operating activities.
  • De.mem (ASX:DEM) distinguished collected cash from Revenue and reported earnings.

De.mem (ASX:DEM) delivers industrial water-treatment systems, membranes, chemicals and site services. On 20 November 2026, its ASX-listed shares were quoted at AUD 0.10, with a 0.00% change for the session. The company’s latest 2026 announcements centre on september cash receipts and operating cash flow, with further milestones disclosed across its operations and Capital programme.

The September disclosure reported collected cash and Operating Cash Flow rather than treating the figures as interchangeable with accounting revenue. Membrane development remains a separate Business initiative.

September Cash Receipts and Operating Cash Flow

De.mem’s September 2026 quarterly activities report disclosed approximately AUD 10.1 million in cash receipts, a 29% increase on the prior corresponding period. It also described its highest positive quarterly operating cash flow to date and a run of 30 consecutive quarters of cash-receipt growth. Cash receipts are amounts collected rather than statutory sales, and operating cash flow is not the same as profit. The distinctions are important when assessing a business that combines recurring treatment services and equipment-related activity.

Industrial Services and Recurring Activity

The company supplies water and wastewater treatment services, chemicals, consumables and membrane technologies to industrial customers. Its Quarterly Report identified a substantial recurring component in service-related revenue and continued activity in Australian operations. It also discussed customer and project wins, which must be assessed on their announced contractual terms. A new framework agreement or equipment order does not automatically produce its full value in the quarter of signature, especially when delivery is scheduled for later reporting periods.

Funding, Projects and Membrane Development

De.mem’s September-quarter report covered ongoing membrane technology development alongside operating activities. The company is working on graphene-oxide-enhanced membranes and domestic filtration applications. Research and certification work should be distinguished from commercial production volumes. Capital allocation therefore spans continuing industrial operations and technology development. Subsequent filings can show operating cash generation, changes in cash balances and the timing of contracted equipment deliveries, rather than assuming that reported orders have already translated into collected cash.

Risks and Uncertainties to Watch

Industrial customers can alter maintenance timing, capital spending or treatment requirements, affecting order patterns. Cash collection may vary with payment schedules, while the cost of chemicals, materials and labour can influence margins. Any claims about continuing quarterly growth require new reported data.

What Investors Are Watching

Future quarterly reports can indicate whether receipts remain elevated, whether positive operating cash flow continues and how Working Capital changes. Disclosures on industrial contracts, membrane product deliveries and recurring service revenue will help assess the composition of activity.

Key Insights

For De.mem, the central issue is operating cash receipts and the composition of industrial water-treatment activity. The reported developments provide concrete milestones, while subsequent disclosures will be needed to assess implementation. Historical financial measures, current operating achievements and prospective plans should remain distinct when interpreting the next reporting period.